Nathaniel Wilson

Assistant Professor of Hematology and Medical Oncology

Winship Cancer Institute of Emory University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Year:

2025

Purpose: Treatment outcomes in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remains dismal. On the basis of both extensive preclinical data and emerging clinical data, treatment with bromodomain and extra-terminal domain inhibitors (BETi) is a potential approach for patients with high-risk myeloid malignancies. Patients and Methods: We conducted a phase I trial to study the safety and efficacy of PLX51107 (BETi) and azacitidine combination therapy in patients with R/R AML and high-risk (HR) MDS and studied mechanisms of resistance to the combination therapy. Results: Thirty-seven patients with HR R/R MDS ( n = 4) and R/R AML ( n = 33) were treated. Sixteen patients (43%) had MECOM gene rearrangement and 7 other patients had TP53 mutation. Median prior number of therapies was three (range 1–9); 97% had received prior hypomethylating agent and 84% prior venetoclax. Overall response rate was 8/37 (22%): complete remission with incomplete platelet recovery ( n = 1); morphologic leukemia-free state ( n = 2); hematologic improvement ( n = 5). The most common nonhematologic toxicities were febrile neutropenia and pneumonia in 12 (32%) patients each; 6 patients (17%) had severe hyperbilirubinemia. RNA-sequencing analysis of mononuclear cells harvested on treatment (day 3) versus pretreatment showed significant changes in mRNA expressions in responders: downregulation of MYC , BCL2 , IL7R , and CDK6 and upregulation of HEXIM1 , CD93 , DCXR , and CDKN1A . Immunoblot analyses confirmed reduction in protein levels of c-Myc, CDK6, BCL2, and BCL-xL, and induction of BRD4 and HEXIM1 protein levels in responders. Conclusions: In a heavily pretreated patient cohort with R/R MDS and AML, PLX51107+ azacitidine was well-tolerated and resulted in modest clinical benefit.

Year:

2025

Year:

2023

Year:

2023

Non‐clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear‐cell RCC (ccRCC), nccRCC typically has a worse prognosis in the metastatic setting, with overall survival durations that are ~10 months shorter. The nccRCC consists of a wide range of different histological subtypes, the majority of which are composed of papillary, chromophobe, renal medullary carcinoma, translocation RCC, collecting duct carcinoma and unclassified RCC. Most clinical trials have either excluded or only included small numbers of patients with nccRCC; owing to the lack of prospective studies focusing on this population, data on response rates and survival outcomes are lacking. NccRCC treatment is a nascent field with various therapeutic modalities and combinations under investigation, often based on data extrapolated from therapeutic studies in ccRCC. We herein review the use and outcomes of cytotoxic chemotherapy, various combination modalities of tyrosine kinase inhibitors and immune checkpoint inhibitors, and targeted agents. We discuss active ongoing clinical trials for patients with nccRCC and future directions in the treatment of this rare disease. Historically, treatment for nccRCC has been adopted from the standard of care for patients with ccRCC, although these treatments are less effective in the nccRCC population. As we begin to understand the underlying biology of these tumors, clinical trials have been able to slowly accrue and include more patients with various subtypes of nccRCC. There remains much room for improvement in this area of need, but there is hope on the horizon.

Year:

2023

Year:

2023

Collaborators (27)

Gautam Borthakur

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Katherine Kurnit

Assistant Professor

University of Chicago Medicine

UNITED STATES
View details

Kaitlin J Basham

Assistant Professor

University of Utah

UNITED STATES
View details

Jianjun Gao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jayastu Senapati

Assistant professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniel Frigo

Scientific Director of Research

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ghayas C. Issa

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marina Konopleva

Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Eleonora Dondossola

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elshad Hasanov

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Paul Corn

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shannon Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Joseph D. Khoury

University of Nebraska Medical Center

UNITED STATES
View details

Jan A. Burger

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Koji Sasaki

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nitin Jain

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Farhad Ravandi

Professor of Medicine, Chief Section of AML

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kapil Bhalla

-

UNITED STATES
View details

Naveen Pemmaraju

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nicholas J. Short

-

UNITED STATES
View details

Warren Fiskus

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yesid Alvarado Valero

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tapan M. Kadia

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elias J. Jabbour

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Courtney D. DiNardo

University of Pennsylvania

UNITED STATES
View details

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Naval G. Daver

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details